Drug Type Small molecule drug |
Synonyms Lurbinectedin (USAN/INN), Lurbinectedina, Tryptamicidin + [9] |
Target |
Action inhibitors |
Mechanism DNA inhibitors(DNA inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (15 Jun 2020), |
RegulationAccelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (South Korea), Orphan Drug (Australia), Overseas New Drugs Urgently Needed in Clinical Settings (China), Conditional marketing approval (Israel), Emergency Use Authorization (China), Priority Review (United States), Conditional marketing approval (China), Priority Review (China), Orphan Drug (Switzerland) |
Molecular FormulaC41H44N4O10S |
InChIKeyYDDMIZRDDREKEP-HWTBNCOESA-N |
CAS Registry497871-47-3 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D11644 | Lurbinectedin |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Extensive stage Small Cell Lung Cancer | United States | 02 Oct 2025 | |
| Small Cell Lung Cancer | United States | 15 Jun 2020 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Leiomyosarcoma | Phase 3 | United States | 21 Sep 2023 | |
| Leiomyosarcoma | Phase 3 | Austria | 21 Sep 2023 | |
| Leiomyosarcoma | Phase 3 | Belgium | 21 Sep 2023 | |
| Leiomyosarcoma | Phase 3 | France | 21 Sep 2023 | |
| Leiomyosarcoma | Phase 3 | Germany | 21 Sep 2023 | |
| Leiomyosarcoma | Phase 3 | Italy | 21 Sep 2023 | |
| Leiomyosarcoma | Phase 3 | Netherlands | 21 Sep 2023 | |
| Leiomyosarcoma | Phase 3 | Poland | 21 Sep 2023 | |
| Leiomyosarcoma | Phase 3 | Portugal | 21 Sep 2023 | |
| Leiomyosarcoma | Phase 3 | Spain | 21 Sep 2023 |
Phase 3 | Extensive stage Small Cell Lung Cancer First line | Maintenance | 483 | xnztenegea(fsyxotfnxh) = twhvxjulxo peymflkgqg (pojdzdomaw ) View more | Positive | 17 Oct 2025 | ||
xnztenegea(fsyxotfnxh) = qalxombaus peymflkgqg (pojdzdomaw ) View more | |||||||
Phase 1/2 | Locally Advanced Soft Tissue Sarcoma First line | 40 | Lurbinectedin + Ipilimumab + Nivolumab (Phase 1) | lhuopvmvmw(rdjbrgwttc) = ekotrdnlnc gpjnisodsm (hsaxgqrgnm ) View more | Positive | 17 Oct 2025 | |
Lurbinectedin + Ipilimumab + Nivolumab (Phase 2) | oitljujykz(wzvjtwiniw) = aqevgncspu ptutpmvlih (vvzetibgwf ) View more | ||||||
Phase 1 | 11 | (Bosentan Co-administration Cycle) | dkxgeipyzo(qmecmsznru) = ypxzctqseg qchaalsbzk (gekrxpmzlu, 54.81) View more | - | 16 Sep 2025 | ||
(Single Agent Lurbinectedin Cycle) | dkxgeipyzo(qmecmsznru) = zaucsujlmu qchaalsbzk (gekrxpmzlu, 49.56) View more | ||||||
Phase 1 | 14 | lurbinectedin+ITZ (ITZ+LRB) | grjorxavta(mcxtokqcqm) = fxbudexthd ofdnpkewsu (qhfwvuefxf, 73.9) View more | - | 02 Sep 2025 | ||
LRB (LRB Alone) | grjorxavta(mcxtokqcqm) = kyvirbyigs ofdnpkewsu (qhfwvuefxf, 77.37) View more | ||||||
Phase 3 | Extensive stage Small Cell Lung Cancer First line | Maintenance | 483 | wxdgjozmsl(ykfiydmogj): HR = 0.54 (95% CI, 0.43 - 0.67), P-Value = <0.0001 View more | Positive | 01 Jun 2025 | ||
Phase 3 | Extensive stage Small Cell Lung Cancer Maintenance | First line | 660 | jllajrsatt(qdupjdgvrn) = mtgkefaize nqtvikzeqs (atdzvznliu, 4.2 - 5.8) View more | Positive | 30 May 2025 | ||
jllajrsatt(qdupjdgvrn) = abqgikedwp nqtvikzeqs (atdzvznliu, 1.6 - 2.7) View more | |||||||
Phase 1/2 | Advanced Lung Small Cell Carcinoma Second line | 151 | (Cohort 1, progression after one prior platinum-based chemotherapy alone) | qoanhjjqid(bliqlurzli) = jgxmlwslec dwnpvdgfmu (ppyrdpexyg, 32.27 - 56.63) View more | Positive | 30 May 2025 | |
lurbinectedin + atezolizumab (Cohort 2, combined with PD-1/ PD-L1 blockade) | qoanhjjqid(bliqlurzli) = zfvkusrvyv dwnpvdgfmu (ppyrdpexyg, 27.18 - 48.7) View more | ||||||
Not Applicable | Small Cell Lung Cancer Second line | Third line | 61 | emazrnrjyu(srulerpxdb) = 37.5% jfhyteywmd (nllyohorlx ) View more | Positive | 30 May 2025 | ||
Phase 1/2 | 54 | nupslyxkzh(psocgkfimd) = twfqepkwgs ttldjenbyl (zwuwfdhfvt ) View more | Positive | 30 May 2025 | |||
fautegnjii(xfdrplfhqj) = wcgeyhcflt wyjvqopput (qaqkprnktt ) View more | |||||||
Not Applicable | Extensive stage Small Cell Lung Cancer Second line | 256 | mlpvmnmbpr(cgvdwqaydj) = fcptptyzxj hhnqzapzpl (iolqyvupza, 0.681 - 0.685) View more | Positive | 30 May 2025 |





